Extracellular proteolysis and cancer: Meeting summary and future directions

Cancer Research

Volumn 63, Issue 19, 2003, Pages 6105-6109

  Matrisian, Lynn M ^a   Sledge Jr , George W ^b   Mohla, Suresh ^c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR;

ADVANCED CANCER; BONE METASTASIS; CANCER; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RESEARCH; CANCER STAGING; CONFERENCE PAPER; DIAGNOSTIC VALUE; DRUG MECHANISM; DRUG RESEARCH; DRUG TOXICITY; ENZYME ACTIVITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION;

CLINICAL TRIALS; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASMS; PROTEASE INHIBITORS;

EID: 0141885138     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Hornebeck, W., Emonard, H., Monboisse, J. C., and Bellon, G. Matrix-directed regulation of pericellular proteolysis and tumor progression. Semin. Cancer Biol., 3: 231-241, 2002.
2. Eglebad, M., and Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer, 2: 163-176, 2002.
3. McCawley, L. J., and Matrisian L. M. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol. Med. Today, 6: 149-156, 2000.
4. Overall, C. M., and Lopez-Otin, C. Startegies for MMP inhibition in cancer: Innovations for the post-trial era. Nat. Rev. Cancer, 2: 657-672, 2002.
5. Coussens, L. M., Fingleton, B., and Matrisian, L. M., Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (Wash. DC), 295: 2387-2392, 2002.
6. Rudek, M. A., Venitz, J., and Figg, W. D., Matrix metalloproteinase inhibitor: do they have a place in anticancer therapy? Pharmacotherapy, 22: 705-720, 2002.
7. Louie, A. Y., Huber, M. M., Ahrens, E. T., Rothbacher, U., Moats, R., Jacobs, R. E., Fraser, S. E., and Meade, T. J. In vivo visualization of gene expression using magnetic resonance imaging. Nat. Biotechnol., 3: 321-325, 2000.
8. Mahmood, U., Tung, C, H., Tang, Y., and Weissleder, R. Feasibility of in vivo multichannel optical imaging of gene expression: experimental study in mice. Radiology, 224: 446-451, 2002.
9. Corthals, G. L., and Nelson, P. S. Large-scale proteomics and its future impact on medicine. Pharmacogenomics J., 1: 15-19, 2001.
10. Duffy, M. J. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence. Clin. Chem., 48: 1194-1197, 2002.
11. Harbeek, N., Kates, R. E., Look, M. P., Meijer-van Gelder, M. E., Klijn, Jan, G. M., Krüger, A., Kiechle, M., Jänicke, F., Schmitt, M., and Fockens J. A. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res., 62: 4617-4622, 2002.
12. Yousef, G. M., and Diamandis, E. P. Expanded human tissue kattikrein family-a novel panel of cancer biomarkers. Tumour Biol., 3: 185-192, 2002.
13. Viner, J. L., Umar, A., and Hawk, E. T. Chemoprevention of colorectal cancer: problems, progress, and prospects. Gastroenterol. Clin. North Am., 4: 971-999, 2002.
14. Rockway, T. W., Nienaber, V., and Giranda, V. L. Inhibitors of the protease domain of urokinase-type plasminogen activator. Curr. Pharm., 28: 2541-2558, 2002.
15. Drummond, A. H., Beckett, P., Brown, P. D., Bone, E. A., Davidson, A. H., Galloway, W. A., Gearing, A. J., Huxley, P., Laber, D., McCourt, M., Whittaker, M., Wood, L. M., and Wright, A. Preclinical and clinical studies of MMP inhibitors in cancer. Ann. N. Y. Acad. Sci., 878: 228-235, 1999.
16. Liu, S., Aaronson, H., Mitola, D., Leppla, S. H., and Bugge, T. H. Potent anti-tumor activity of a urokinase-activated engineered anthrax toxin. Proc. Natl. Acad. Sci. USA, 100: 657-662, 2003.
17. Heissig, B., Hattori, K., Dias, S., Friedrich, M., Ferris, B., Hackett, N. R., Crystal, R. G., Besmer, P., Lyden, D., Moore, M. A., Werb, Z., and Rafii, S. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell, 109: 625-637, 2002.
18. Blobel, C. P. Remarkable roles of proteolysis on and beyond the cell surface. Curr. Opin. Cell Biol., 12: 606-612, 2000.
19. Lin, S. Y., Makino, K., Xia, W., Matin, A., Wen, Y., Kwong, K. Y., Bourguignon, L., and Hung, M. C. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat. Cell Biol., 3: 802-808, 2001.
20. Wolf, K., Mazo, I., Leung, H., Engelke, K., von Andrian, U. H., Deryugina, E. I., Strongin, A. Y., Brocker, E. B., and Friedl, P. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J. Cell Biol., 160: 267-277, 2003.
21. Roshy, S., Sloane, B. F., and Moin, K. Pericellular cathepsin B and malignant progression. Cancer Metastasis Rev., 22: 271-286, 2003.
22. Al-Mehdi, A. B., Tozawa, K., Fisher, A. B., Shientag, L., Lee, A., and Muschel, R. J., Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat. Med., 1: 100-102, 2000.
23. Wong, C. W., Song, C., Grimes, M. M., Fu, W., Dewhirst, M. W., Muschel, R. J., and Al-Mehdi, A. B. Intravascular location of breast cancer cells after spontaneous metastasis to the lung. Am. J. Pathol., 161: 749-753, 2002.
24. Quaranta V. Cell migration through extracellular matrix: membrane-type metalloproteinases make the way. J. Cell Biol., 149: 1167-1170, 2000.
25. Hendrix, M. J. C., Seftor, E. A., Hess, A. R., and Seftor, R. E. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat. Rev. Cancer, 3: 411-421, 2003.
26. Wu, W., Mwale, F., Tchetina, E., Kojima, T., Yasuda, T., and Poole, A. R. Cartilage matrix resorption in skeletogenesis. Novartis Found Symp., 232: 158-170, 2001.
27. Cher, M. L., Biliran, H. R., Jr., Bhagat, S., Meng, Y., Che, M., Lockett, J., Abrams, J., Fridman, R., Zachareas, M., and Sheng, S. Maspin expression inhibits osteolysis, tumor growth and angiogenesis in a model of prostate cancer bone metastasis. Proc. Natl. Acad. Sci. USA, 100: 7847-7852, 2003.
28. Nemeth, J. A., Harb, J. F., Barroso, U., Jr., He, Z., Grignon, D. J., and Cher, M. L. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res., 59: 1987-1993, 1999.
29. Waltham, M., Tester, A., Ruangpanit, N., Bills, M., Shalinsky, D. R., and Thompson, E. W. Prinomastat inhibits primary tumor growth and retards osteolytic disease in xenograft models of breast cancer metastasis. In: 23rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 2000.
30. Giranda, V. L., and Matrisian, L. M. The protease consortium: an alliance to advance the understanding of proteolytic enzymes as therapeutic targets for cancer. Mol. Carcinog., 3: 139-142, 1999.